bisnafide has been researched along with Colonic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrens, CH; Behrens, DL; Chen, SF; Fredericks, JR; Kirshenbaum, MR; Papp, LM; Polkus, ST; Sipple, P; Stafford, MM; Sun, JH | 1 |
| Burns-Horwitz, PE; Chen, SF; Czerniak, PM; Dexter, DL; Diamond, MA; Diamond, RJ; McRipley, RJ; Miller, JL; Page, RJ; Sun, JH | 1 |
| Behrens, CH; Cheshire, PJ; Dexter, DL; Gross, JL; Hallman, JC; Houghton, JA; Houghton, PJ; McRipley, RJ; Sun, JH | 1 |
3 other study(ies) available for bisnafide and Colonic Neoplasms
| Article | Year |
|---|---|
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic Neoplasms; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoquinolines; KB Cells; Kinetics; Leucine; Leukemia L1210; Leukemia P388; Mammary Neoplasms, Experimental; Melanoma; Melanoma, Experimental; Mesylates; Mice; Mitoxantrone; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured; Uridine | 1994 |
Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Isoquinolines; Leukemia L1210; Leukemia P388; Lung Neoplasms; Male; Mesylates; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Topics: Adenocarcinoma; Adolescent; Adult; Analysis of Variance; Animals; Antineoplastic Agents; Child; Colonic Neoplasms; Drug Resistance; Female; Humans; Isoquinolines; Mesylates; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 1994 |